Trial from ClinicalTrials.gov

For full trial details, please see the original record at



Trial ID
NCT02442349
Ethics application status
Date submitted
11/05/2015
Date registered
11/05/2015
Date last updated
4/08/2017

Titles & IDs
Public title
Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
Scientific title
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene
Secondary ID [1] 0 0
D5160C00017
Universal Trial Number (UTN)
Trial acronym
AURA17
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: drugs - AZD9291

Experimental: AZD9291 - Once daily tablet 80 mg


Treatment: drugs: AZD9291
Once daily tablet 80 mg

Intervention code [1] 0 0
Treatment: drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective Response Rate (ORR) According to RECIST 1.1 - Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): >= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (according to independent review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.
Timepoint [1] 0 0
RECIST tumour assessments every 6 weeks from time of first dose until objective disease progression, for an average of approximately 12 months. Results are based on the data cut off of 04 March 2016 (about 18 weeks after LSFD).
Secondary outcome [1] 0 0
Disease Control Rate (DCR) According to RECIST 1.1 - Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): >= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): >= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of >=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. DCR is the percentage of patients with best response of CR, PR or SD (according to independent review), prior to progression (PD) or further anti-cancer therapy.
Timepoint [1] 0 0
RECIST tumour assessments every 6 weeks from time first dose until date of progression, for an average of approximately 12 months. Results are based on the data cut off of 04 March 2016 (about 18 weeks after LSFD).

Eligibility
Key inclusion criteria
- Aged at least 18 years. Patient from Asia Pacific will be enrolled only.

- Locally advanced or metastatic NSCLC, not amenable to curative surgery or
radiotherapy.

- Radiological documentation of disease progression on the last treatment administered
prior to enrolling in the study: following 1st line EGFR TKI treatment but who have
not received further treatment OR following prior therapy with an EGFR TKI and a
platinum-based doublet chemotherapy. Patients may have also received additional lines
of treatment.

- Documented EGFR mutation (at any time since the initial diagnosis of NSCLC) known to
be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R,
L861Q).

- Patients must have central confirmation of tumour T790M mutation positive status from
a biopsy sample taken after confirmation of disease progression on the most recent
treatment regimen.

- World Health Organisation (WHO) performance status 0-1 with no deterioration over the
previous 2 weeks and a minimum life expectancy of 12 weeks.

- At least one lesion, not previously irradiated and not chosen for biopsy during the
study screening period, that can be accurately measured at baseline as =10mm in the
longest diameter (except lymph nodes which must have short axis =15mm) with
computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for
accurate repeated measurements.

- Females of child-bearing potential using contraception and must have a negative
pregnancy test.
Minimum age
18 Years
Maximum age
130 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Treatment with an EGFR-TKI (eg, erlotinib, gefitinib, icotinib or afatinib) within 8
days or approximately 5x half-life of study entry; any cytotoxic chemotherapy,
investigational agents or other anticancer drugs within 14 days of study entry;
previous treatment with AZD9291 or a 3rd generation EGFR TKIs; Major surgery within 4
weeks of study entry; radiotherapy treatment to more than 30% of the bone marrow or
with a wide field of radiation within 4 weeks of study entry; currently receiving
treatment with potent inhibitors or inducers of CYP3A4.

- Any unresolved toxicities from prior therapy.

- Unstable spinal cord compression or brain metastases.

- Severe or uncontrolled systemic diseases, including uncontrolled hypertension and
active bleeding diatheses or infection.

- Refractory nausea and vomiting, chronic gastrointestinal diseases or bowel resection.

- Cardiac disease.

- Past medical history of interstitial lung disease, drug-induced interstitial lung
disease, radiation pneumonitis which required steroid treatment, or any evidence of
clinically active interstitial lung disease.

- Inadequate bone marrow reserve or organ function.

Study design
Purpose of the study
Treatment
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Current
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Kogarah
Recruitment hospital [2] 0 0
Research Site - Nedlands
Recruitment hospital [3] 0 0
Research Site - Woolloongabba
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
6009 - Nedlands
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
China
State/province [1] 0 0
Beijing
Country [2] 0 0
China
State/province [2] 0 0
Changchun
Country [3] 0 0
China
State/province [3] 0 0
Chengdu
Country [4] 0 0
China
State/province [4] 0 0
Chongqing
Country [5] 0 0
China
State/province [5] 0 0
Chongqin
Country [6] 0 0
China
State/province [6] 0 0
Fuzhou
Country [7] 0 0
China
State/province [7] 0 0
Haikou
Country [8] 0 0
China
State/province [8] 0 0
Hangzhou
Country [9] 0 0
China
State/province [9] 0 0
Harbin
Country [10] 0 0
China
State/province [10] 0 0
Ji Nan
Country [11] 0 0
China
State/province [11] 0 0
Nanjing
Country [12] 0 0
China
State/province [12] 0 0
Shanghai
Country [13] 0 0
China
State/province [13] 0 0
Wuhan
Country [14] 0 0
China
State/province [14] 0 0
Xi'an
Country [15] 0 0
China
State/province [15] 0 0
Zhengzhou
Country [16] 0 0
Korea, Republic of
State/province [16] 0 0
Goyang-si
Country [17] 0 0
Korea, Republic of
State/province [17] 0 0
Seongnam-si
Country [18] 0 0
Korea, Republic of
State/province [18] 0 0
Seoul

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia
Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease
has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor
Receptor Gene
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries
Contact person responsible for updating information